Lunai Bioworks Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LNAI research report →
Price Chart
About the company
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
- CEO
- David H. Weinstein
- IPO
- 2025
- Employees
- 12
- HQ
- Sacramento, CA, US
Get TickerSpark's AI analysis on LNAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $829.68K
- P/E
- -0.20
- PEG
- -0.00
- P/S
- 15.96
- P/B
- -0.08
- EV/EBITDA
- 118.11
- Div Yield
- 0.00%
- Gross Margin
- -79.88%
- Op Margin
- -15129.29%
- Net Margin
- -6851.97%
- ROE
- 31.55%
- ROIC
- 0.10%
Latest fiscal year · YoY change
- Revenue
- $51.99K+0.0%
- Gross Profit
- $-41,530+67.8%
- Op Income
- $-7,866,018
- Net Income
- $-3,562,479+98.0%
- EPS
- $-1.06+98.8%
- OCF Growth
- -67054.7%
- FCF Growth
- -67070.4%
- 52W High
- $13.28
- 52W Low
- $0.14
- 50D MA
- $1.61
- 200D MA
- $2.91
- Beta
- 0.35
- RSI (14)
- 13
- Avg Volume
- 405.97K
No earnings-call transcripts are available for LNAI yet.
- Free Float
- 61.6%
- Shares Outstanding
- 5.03M
- Float Shares
- 3.10M
of shares held by institutions
1 13F filers
Held by 6 ETFs
Biggest fund positions in LNAI by dollar value.
Our LNAI coverage
Recent articles, reports, and earnings notes.
No research on LNAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LNAI report →Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
prnewswire.com · Oct 22
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
prnewswire.com · Sep 22
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
prnewswire.com · Sep 16
Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint
prnewswire.com · Sep 4
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit
prnewswire.com · Aug 27
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
prnewswire.com · Aug 4
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
prnewswire.com · Aug 4
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
prnewswire.com · Jun 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.